10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $165.02 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.03% ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

In a report released today, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target of ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...